We showed that the addition of the peptide-based PD1 antagonists to one of the established malaria vaccination regimens ostensibly expanded and doubled the level of malaria-specific CD8+ T-cell response and improved the survival of mice upon malaria challenge. The gene discussed is PDCD1; the disease is malaria.